한음이 발표한 의학논문
This study evaluates the safety and effectiveness of the main reader's return to memory loss (for forgetfulness) of patients with hardness cognitive disorder.
Recently, degenerative diseases also show a high prevalence of diseases due to the aging population due to extended life expectancy, and with dementia confirm the validity and safety of the main readbeing the main cause of death following cancer, heart disease and stroke, many people are paying keen attention to aging.
Currently, there is no clear cure for hardness cognitive disorder, and a variety of alternative treatments are being tried. A variety of oriental medicine is being performed to improve memory and cognition, and various clinical studies related to cognitive function have been reported. However, random control clinical research on hardness cognitive disorders using Chinese medicine is still not active.
In this clinical test, we want toer for one of the diseases of forgetfulness.
Applicants should be informed about the clinical trial, sign the agreement, and give the subject ID code to the subjects who will participate in the test according to the selection and exclusion criteria, and carry out the clinical test divided into the test group and the control group. Each subject will be given 7 visits to the test laboratory for 12 weeks after screening, and will receive the test and drug payment. After 12 weeks of dosing, visit the institution one more time to check for abnormalities and analyze the treatment effects.
[원문 보기 클릭]